Apidra Now on Pharmacy Shelves


By: Daniel Trecroci

On February 28, 2006, sanofi-aventis announced that its fast-actingApidra (insulin glulisine [rDNA origin] injection) is now available byprescription in the United States. Apidra was granted FDA approval inApril 2004.

Sanofi-aventis says that Apidra should be used in regimens thatinclude a longer-acting insulin or basal insulin analogue such asLantus.

Sanofi-aventis also announced that Apidra cartridges are nowavailable for use with the OptiClik insulin pen, which is also currentlyapproved for use with Lantus.

In a sanofi-aventis press release, Richard M. Bergenstal, MD,executive director of the International Diabetes Center at ParkNicollet, Minneapolis, Minnesota, says, “Controlling mealtimeblood sugar spikes is a crucial part of managing diabetes. Apidra is awelcome addition to the armamentarium of all healthcare professionalswho treat adults with diabetes.”

Source: sanofi-aventis



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.